오클라시티닙

투여 방법

가능한 부작용

• Gastrointestinal upset (vomiting, diarrhea, anorexia)
• Lethargy
• Increased susceptibility to infections (e.g., pyoderma, otitis, demodicosis, pneumonia)
• Transient decreases in leukocytes and serum globulins
• Potential exacerbation of neoplastic conditions
• Histiocytomas or papillomas (benign skin masses)

주의사항 및 금기

• Dogs less than 12 months of age
• Dogs weighing less than 3 kg
• Dogs with severe systemic infections
• Breeding, pregnant, or lactating dogs
• Dogs with evidence of immune suppression (e.g., hyperadrenocorticism)
• Dogs with a history of progressive malignant neoplasia
• Use with caution in dogs with a history of recurrent infections or neoplasia. **Routine monitoring** for the development of infections (skin, ears, systemic) and abnormal growths is essential. > **Note:** Oclacitinib is not approved for use in cats, and its safety and efficacy profile in felines is not fully established, though it is sometimes used off-label by dermatologists.

약물 상호작용

• Corticosteroids: Increased risk of immunosuppression and secondary infections.
• Cyclosporine: Increased risk of profound immunosuppression.
• Modified live vaccines: Potential for decreased vaccine efficacy or vaccine-induced illness due to immunomodulation.

자주 묻는 질문